A novel bioerodible ocular implant that continuously releases kamuvudine K8 (K8) — a dual inflammasome inhibitor — significantly slowed the progression of geographic atrophy (GA), a leading cause of irreversible vision loss, in a phase II clinical trial. Presented at the American Academy of Ophthalmology meeting, the results showed that the mid-level dose of K8 reduced GA lesion growth by 54% at 6 months compared to untreated fellow eyes, with the effect accelerating over time. Crucially, no drug-related adverse events were observed at any dose level.

Unlike the two currently approved GA treatments — both complement inhibitors — K8 works by blocking two inflammasomes, NLRP3 and NLRC4, which are implicated in retinal pigmented epithelium degeneration. It also offers practical advantages: quarterly dosing, no refrigeration required, and a preloaded injector. A prespecified visual acuity analysis also favored K8-treated eyes by +4 letters, though the trial wasn't powered for that endpoint.

By the Numbers:

• 54% reduction in GA lesion growth rate at 6 months (mid-level dose)
• 43% → 70% growth rate reduction from months 0–3 to months 3–6
• 25 of 30 patients showed slower GA growth in the treated vs. untreated eye
• +4 letters improvement in best-corrected visual acuity favoring K8 (P=0.004)

Why it matters: GA currently has very limited treatment options, and existing therapies require frequent dosing under refrigeration. K8's strong early efficacy signal, clean safety profile, and patient-friendly delivery could represent a meaningful step forward — if confirmed in the larger phase III trial now being planned.